A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.

导出原文传递

翻译打印收藏纠错

作者： Fox, Christopher P. ^[1] ; Arcaini, Luca ^[2] ; Hernandez-Ilizaliturri, Grancisco ^[3] ; Tabah, Ashley ^[4] ; Parker, Christopher ^[5] ; Jones, Jeffrey ^[6] ; Abouzaid, Safiya ^[7] ; Watkins, Claire ; Bachy, Emmanuel

作者单位： Nottingham Univ Hosp NHS Trust, Nottingham, England ^[1] Celgene Ltd, Uxbridge, Middx, England ^[2] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA ^[3] Fdn IRCCS Policlin San Matteo, Pavia, Italy ^[4] Celgene Corp, Summit, NJ USA ^[5] Clarostat Consulting, Alderley Edge, England ^[6] Hosp Civils Lyon, Ctr Hop Lyon Sud, Lyon, France ^[7]

发布时间 2021-01-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

American Journal of Hematology

2019年94卷S2期

S29-S30页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.

American Journal of Hematology

相似文献

American Journal of Hematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.

American Journal of Hematology

相似文献

American Journal of Hematology

相关期刊

检索历史清除